keyword
MENU ▼
Read by QxMD icon Read
search

burkitt s leukemia

keyword
https://www.readbyqxmd.com/read/29112016/b-lymphoblastic-leukemia-lymphoma-with-burkitt-like-morphology-and-igh-myc-rearrangement-report-of-3-cases-in-adult-patients
#1
Yiting Li, Gunjan Gupta, Ari Molofsky, Yi Xie, Nader Shihabi, Jane McCormick, Elaine S Jaffe
Isolated MYC rearrangement without other recurrent genetic abnormalities is rare in B lymphoblastic leukemia/lymphoma (B-ALL/LBL), with most cases reported in pediatric patients. We report 3 adult cases with lymphoblasts showing a precursor B cell immunophenotype, and isolated MYC/IGH translocation. All 3 cases occurred in male patients with initial presentation of diffuse lymphadenopathy. Cases 1 and 2 had B-ALL with significantly increased lymphoblasts in peripheral blood and bone marrow. Case 3, a patient with human immunodeficiency virus infection, had the diagnosis of B-LBL made on a retroperitoneal lymph node biopsy and had no peripheral blood or bone marrow involvement...
November 3, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29022001/data-supporting-the-functional-role-of-eleven-nineteen-lysine-rich-leukemia-3-ell3-in-b-cell-lymphoma-cell-line-cells
#2
Lou-Ella M M Alexander, January Watters, Jessica A Reusch, Michelle Maurin, Brook S Nepon-Sixt, Katerina Vrzalikova, Mark G Alexandrow, Paul G Murray, Kenneth L Wright
The data presented here are related to the research article entitled "Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival" (Alexander et al., 2017) [1]. The cited research article characterizes Eleven-nineteen Lysine-rich Leukemia 3 (ELL3) expression in the B cell compartment and functional dependence in B lymphoma cell lines. This data report describes the mRNA expression pattern in a panel of cell lines representing the B cell compartment, supplementing the protein expression data presented in the associated research report...
December 2017: Data in Brief
https://www.readbyqxmd.com/read/28858629/selective-expression-of-the-transcription-elongation-factor-ell3-in-b-cells-prior-to-ell2-drives-proliferation-and-survival
#3
Lou-Ella M M Alexander, January Watters, Jessica A Reusch, Michelle Maurin, Brook S Nepon-Sixt, Katerina Vrzalikova, Mark G Alexandrow, Paul G Murray, Kenneth L Wright
B cell activation is dependent on a large increase in transcriptional output followed by focused expression on secreted immunoglobulin as the cell transitions to an antibody producing plasma cell. The rapid transcriptional induction is facilitated by the release of poised RNA pol II into productive elongation through assembly of the super elongation complex (SEC). We report that a SEC component, the Eleven -nineteen Lysine-rich leukemia (ELL) family member 3 (ELL3) is dynamically up-regulated in mature and activated human B cells followed by suppression as B cells transition to plasma cells in part mediated by the transcription repressor PRDM1...
November 2017: Molecular Immunology
https://www.readbyqxmd.com/read/28729148/clinical-grade-expanded-regulatory-t-cells-prevent-graft-versus-host-disease-while-allowing-a-powerful-t-cell-dependent-graft-versus-leukemia-effect-in-murine-models
#4
Beatrice Del Papa, Loredana Ruggeri, Elena Urbani, Stefano Baldoni, Debora Cecchini, Tiziana Zei, Roberta Iacucci Ostini, Barbara Crescenzi, Alessandra Carotti, Antonio Pierini, Paolo Sportoletti, Paolo Di Bartolomeo, Franca Falzetti, Cristina Mecucci, Andrea Velardi, Massimo F Martelli, Mauro Di Ianni
We developed a good manufacturing practices-compatible expansion protocol to improve number and purity of regulatory T cells (Tregs) available for clinical trials. Six clinical-grade separation procedures were performed, followed by expansion with high-dose interleukin (IL)-2, anti-CD3/anti-CD28 TCR stimulation, and rapamycin for 19 days achieving a median of 8.5-fold (range, 6.25 to 13.7) expansion. FOXP3 expression was stably maintained over the culture period, while the percentage of CD127 was significantly reduced...
July 17, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28553616/the-oncolytic-virotherapy-era-in-cancer-management-prospects-of-applying-h-1-parvovirus-to-treat-blood-and-solid-cancers
#5
Assia L Angelova, Mathias Witzens-Harig, Angel S Galabov, Jean Rommelaere
Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established for T-NHL/leukemia. As presentation in both B- and T-NHL/leukemia patients is often aggressive and as prognosis for relapsed disease is especially dismal, this cancer entity poses major challenges and requires innovative therapeutic approaches. In clinical trials, oncolytic viruses (OVs) have been used against refractory multiple myeloma (MM)...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28492808/famlf-is-a-target-of-mir-181b-in-burkitt-lymphoma
#6
J G Li, Y Ding, Y M Huang, W L Chen, L L Pan, Y Li, X L Chen, Y Chen, S Y Wang, X N Wu
Burkitt lymphoma (BL) is a highly malignant non-Hodgkin's lymphoma that is closely related to the abnormal expression of genes. Familial acute myelogenous leukemia related factor (FAMLF; GenBank accession No. EF413001.1) is a novel gene that was cloned by our research group, and miR-181b is located in the intron of the FAMLF gene. To verify the role of miR-181b and FAMLF in BL, RNAhybrid software was used to predict target site of miR-181b on FAMLF and real-time quantitative PCR (RQ-PCR) was used to detect expression of miR-181b and FAMLF in BL patients, Raji cells and unaffected individuals...
May 4, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/28427156/the-effects-of-dleu1-gene-expression-in-burkitt-lymphoma-bl-potential-mechanism-of-chemoimmunotherapy-resistance-in-bl
#7
Sanghoon Lee, Wen Luo, Tishi Shah, Changhong Yin, Timmy O'Connell, Tae-Hoon Chung, Sherrie L Perkins, Rodney R Miles, Janet Ayello, Erin Morris, Lauren Harrison, Carmella van de Ven, Mitchell S Cairo
Following a multivariant analysis we demonstrated that children and adolescents with Burkitt lymphoma (BL) and a 13q14.3 deletion have a significant decrease in event free survival (EFS) despite identical short intensive multi-agent chemotherapy. However, how this deletion in the 13q14.3 region is associated with a significant decrease in EFS in children and adolescents with BL is largely unknown. The gene Deleted in Lymphocytic Leukemia 1 (DLEU1) is located in the region of 13q14.3. Here, we report that DLEU1 expression is implicated in the regulation of BL programmed cell death, cell proliferation, and expression of apoptotic genes in transcription activator-like effector nuclease (TALEN)s-induced DLEU1 knockdown and DLEU1 overexpressing BL cell lines...
April 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28360415/hiv-tat-induces-a-prolonged-myc-relocalization-next-to-igh-in-circulating-b-cells
#8
D Germini, T Tsfasman, M Klibi, R El-Amine, A Pichugin, O V Iarovaia, C Bilhou-Nabera, F Subra, Y Bou Saada, A Sukhanova, D Boutboul, M Raphaël, J Wiels, S V Razin, S Bury-Moné, E Oksenhendler, M Lipinski, Y S Vassetzky
With combined antiretroviral therapy (cART), the risk for HIV-infected individuals to develop a non-Hodgkin lymphoma is diminished. However, the incidence of Burkitt lymphoma (BL) remains strikingly elevated. Most BL present a t(8;14) chromosomal translocation which must take place at a time of spatial proximity between the translocation partners. The two partner genes, MYC and IGH, were found colocalized only very rarely in the nuclei of normal peripheral blood B-cells examined using 3D-FISH while circulating B-cells from HIV-infected individuals whose exhibited consistently elevated levels of MYC-IGH colocalization...
November 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28297626/clinical-applications-of-the-genomic-landscape-of-aggressive-non-hodgkin-lymphoma
#9
REVIEW
Andrea B Moffitt, Sandeep S Dave
In this review, we examine the genomic landscapes of lymphomas that arise from B, T, and natural killer cells. Lymphomas represent a striking spectrum of clinical behaviors. Although some lymphomas are curable with standard therapy, the majority of the affected patients succumb to their disease. Here, the genetic underpinnings of these heterogeneous entities are reviewed. We consider B-cell lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, and primary mediastinal B-cell lymphoma...
March 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28056294/-the-understanding-of-epstein-barr-virus-associated-lymphoproliferative-disorder
#10
X G Zhou, Y L Zhang, J L Xie, Y H Huang, Y Y Zheng, W S Li, H Chen, F Liu, H X Pan, P Wei, Z Wang, Y C Hu, K Y Yang, H L Xiao, M J Wu, W H Yin, K Y Mei, G Chen, X C Yan, G Meng, G Xu, J Li, S F Tian, J Zhu, Y Q Song, W J Zhang
In recent years, there are increasing articles concerning Epstein-Barr virus associated lymphoproliferative disorder (EBV+ LPD), and the name of EBV+ LPD is used widely. However, the meaning of EBV+ LPD used is not the same, which triggered confusion of the understanding and obstacles of the communication. In order to solve this problem. Literature was reviewed with combination of our cases to clarify the concept of EBV+ LPD and to expound our understanding about it. In general, it is currently accepted that EBV+ LPD refers to a spectrum of lymphoid tissue diseases with EBV infection, including hyperplasia, borderline lesions, and neoplastic diseases...
December 8, 2016: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/27910030/recurrent-cytogenetic-abnormalities-in-non-hodgkin-s-lymphoma-and-chronic-lymphocytic-leukemia
#11
Edmond S K Ma
Characteristic chromosomal translocations are found to be associated with subtypes of B-cell non-Hodgkin lymphoma (NHL), for example t(8;14)(q24;q32) and Burkitt lymphoma, t(14;18)(q32;q21) and follicular lymphoma, and t(11;14)(q13;q32) in mantle cell lymphoma. Only few recurrent cytogenetic aberrations have been identified in the T-cell NHL and the best known is the ALK gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma. Since lymph node or other tissue is seldom submitted for conventional cytogenetics study, alternative approaches for translocation detection are polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH)...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27512341/concomitant-classic-hodgkin-lymphoma-of-lymph-node-and-cmyc-positive-burkitt-leukemia-lymphoma-of-the-bone-marrow-presented-concurrently-at-the-time-of-presentation-a-rare-combination-of-discordant-lymphomas
#12
Dina S Soliman, Shehab Fareed, Einas Alkuwari, Halima El-Omri, Ahmad Al-Sabbagh, Amna Gameel, Mohamed Yassin
Discordant lymphoma is rare condition in which different types of malignant lymphomas occurring in different anatomic sites. The two diseases may present clinically as concurrent or sequential disease (10). Herein we are reporting a Pakistani female in her 60s, a carrier of hepatitis B virus with multiple comorbidities presented with cervical lymphadenopathy, diagnosed as Hodgkin's lymphoma, mixed cellularity. During the staging workup, the patient was discovered to have extensive bone marrow (BM) involvement by Burkitt leukaemia/lymphoma (BL)...
2016: Clinical Medicine Insights. Blood Disorders
https://www.readbyqxmd.com/read/27356578/differential-expression-of-cd150-slamf1-in-normal-and-malignant-b-cells-on-the-different-stages-of-maturation
#13
I M Gordiienko, L M Shlapatska, L M Kovalevska, S P Sidorenko
UNLABELLED: Within B-cell lineage cell surface receptor CD150/SLAMF1 is broadly expressed starting from pre-B cells with upregulation toward plasma cells. However, expression of CD150 is rather limited on the surface of malignant B cells with the block of differentiation at the different stages of maturation. The aim of our work was to explore CD150 expression both on protein and mRNA levels with the emphasis on CD150 isoforms in malignant B-cell lines at the different stages of maturation in comparison with their normal B cell counterparts...
June 2016: Experimental Oncology
https://www.readbyqxmd.com/read/27041560/targeting-ck2-driven-non-oncogene-addiction-in-b-cell-tumors
#14
REVIEW
E Mandato, S Manni, F Zaffino, G Semenzato, F Piazza
Genetic mutations of oncogenes often underlie deranged cell growth and altered differentiation pathways leading to malignant transformation of B-lymphocytes. However, addiction to oncogenes is not the only drive to lymphoid tumor pathogenesis. Dependence on non-oncogenes, which act by propelling basic mechanisms of cell proliferation and survival, has also been recognized in the pathobiology of lymphoid leukemias, lymphomas and multiple myeloma. Among the growing number of molecules that may uphold non-oncogene addiction, a key place is increasingly being recognized to the serine-threonine kinase CK2...
November 24, 2016: Oncogene
https://www.readbyqxmd.com/read/26991956/subtype-specific-incidence-rates-of-lymphoid-malignancies-in-hong-kong-compared-to-the-united-states-2001-2010
#15
COMMENT
Bryan A Bassig, Wing-Yan Au, Oscar Mang, Roger Ngan, Lindsay M Morton, Dennis K M Ip, Wei Hu, Tongzhang Zheng, Wei Jie Seow, Jun Xu, Qing Lan, Nathaniel Rothman
Clinical studies of lymphoid malignancies (LMs) have suggested that the descriptive patterns of LMs differ in East Asia compared to Western populations. However, there are very limited available data on population-based, subtype-specific incidence rates of LMs in the East Asian population, particularly in Chinese. Using data from the Hong Kong (HK) Cancer Registry and United States (U.S.) SEER Program, we calculated and compared age-adjusted incidence rates of LM subtypes in HK to those in Whites and Asians living in the U...
2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/26939705/protein-kinase-inhibitor-h89-enhances-the-activity-of-pseudomonas-exotoxin-a-based-immunotoxins
#16
Xiufen Liu, Fabian Müller, Alan S Wayne, Ira Pastan
HA22 (Moxetumomab pasudotox) is a recombinant immunotoxin (RIT), composed of an anti-CD22 Fv fused to a truncated portion of Pseudomonas exotoxin A. HA22 is in clinical trials to treat patients with hairy cell leukemia and acute lymphoblastic leukemia (ALL). LMB-11 is an improved variant of HA22 with reduced immunogenicity, has a longer half-life in the blood and high activity in vitro and in a Burkitt lymphoma model in vivo Searching for RIT enhancing combination therapies, we found the protein kinase A inhibitor H89 to enhance LMB-11 and HA22 activity 5- to 10-fold on ALL cell lines and on patient-derived ALL samples...
May 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/26489677/b-lymphoblastic-leukemia-with-a-novel-t-11-15-q23-q15-and-unique-burkittoid-morphologic-and-immunophenotypic-findings-in-a-9-year-old-boy
#17
Megan C Smith, Megan K Kressin, Eric Crawford, Xuan J Wang, Annette S Kim
B lymphoblastic leukemia is a B progenitor cell neoplasm with a range of immature immunophenotypes and several associated cytogenetic lesions. In contrast, Burkitt leukemia/lymphoma is a mature B lymphocyte neoplasm with a characteristic germinal center immunophenotype and MYC rearrangement. With modern immunophenotyping and cytogenetic methods, the distinction between these 2 entities is seldom ambiguous. Herein, we report a case of a 9-year-old white boy with circulating leukemic cells that demonstrate morphologic overlap between Burkitt leukemia and B lymphoblastic leukemia...
2015: Laboratory Medicine
https://www.readbyqxmd.com/read/26450341/burkitt-leukemia-limited-to-the-bone-marrow-has-a-better-prognosis-than-burkitt-lymphoma-with-bone-marrow-involvement-in-adults
#18
Joo Y Song, Girish Venkataraman, Yuri Fedoriw, Alex F Herrera, Tanya Siddiqi, Mir B Alikhan, Young S Kim, Joyce Murata-Collins, Dennis D Weisenburger, Xueli Liu, Amy S Duffield
Burkitt lymphoma patients with bulky disease often have bone marrow involvement. However, leukemic presentation of Burkitt lymphoma in the absence of a mass (pure Burkitt leukemia; PBL) is uncommon. Both PBL and Burkitt lymphoma/leukemia, presenting with a tumor mass and marrow involvement (BLL), are considered stage IV disease, which is associated with a poor prognosis. However, there is limited information on the prognosis in adults with PBL because they have typically been included in cohorts of patients with BLL...
2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/26449660/array-based-comparative-genomic-hybridization-detects-copy-number-variations-with-prognostic-relevance-in-80-of-all-with-normal-karyotype-or-failed-chromosome-analysis
#19
V Mühlbacher, T Haferlach, W Kern, M Zenger, S Schnittger, C Haferlach
Pretreatment cytogenetics is an important parameter for risk stratification and therapy approach in acute lymphoblastic leukemia (ALL). However, in up to 30% of cases, chromosome banding analysis (CBA) fails or reveals a normal karyotype. To characterize the subset of ALL with normal karyotype or failed CBA, we performed fluorescence in situ hybridization (FISH) or PCR for BCR-ABL1 and MLL rearrangements as well as array comparative genomic hybridization (aCGH) in 186 adult patients. We further carried out FISH for MYC in cases with Burkitt leukemia phenotype...
February 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/26390720/-therapy-for-burkitt-s-lymphoma-according-to-the-bl-m-04-protocol-12-year-experience
#20
EDITORIAL
E A Baryakh, N G Tyurina, V I Vorobyev, E G Gemdzhyan, Ya K Mangasarova, G A Klyasova, A M Kovrigina, T N Obukhova, E E Zvonkov, M A Vernyuk, A M Chervontseva, Yu Yu Polyakov, А Е Misyurina, T T Valiev, V A Zherebtsova, A U Magomedova, G M Galstyan, K V Yatskov, E S Nesterova, A I Vorobyev, S K Kravchenko
AIM: To evaluate the efficiency and toxicity of the intensive Burkitt's lymphoma (BL) therapy protocol BL-M-04. SUBJECTS AND METHODS: A total of 70 patients diagnosed with BL, including 45 men and 25 women whose age was 15 to 62 years (median age 31 years), were followed up in 2003 to 2014. Stage I (according to S. Murphy) was diagnosed in 4 (5.7%) patients; II in 9 (12.9%), III in 25 (35.7%), IV in 11 (15.7%), and Burkitt's leukemia in 21 (30%). There were tumor involvements of the bone marrow and central nervous system in 23 (32...
2015: Terapevticheskiĭ Arkhiv
keyword
keyword
75586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"